Your pipeline can be more
valuable with
"Translational" science

Contact Us
Strategy compass
AIMS

Bring your problems
and find answers

Answering your questions

You may encounter difficulties and have various questions regarding your pipelines.

We can provide you with the most suitable strategies to troubleshoot your issues.

Our Services

  • 1/6

    Development Rationale and Goal Alignment

    Align disease, patient population, and pipeline selection into one development logic.

    AIMS reviews the candidate mechanism, available evidence, disease characteristics, target population, and competitive landscape to define why this disease, why this patient group, and why this pipeline should be prioritized.

    View more
  • 2/6

    Core Evidence Generation Roadmap

    Design which evidence should be generated first and when development decisions should be made.

    AIMS defines how nonclinical, CMC, clinical pharmacology, and clinical evidence will be used in development decisions, then aligns evidence sequence and decision criteria to enable Quick-win / Fast-fail.

    View more
  • 3/6

    Nonclinical / Clinical Study Execution Support

    Plan the right study and support sponsor-side execution through CROs, vendors, and trial sites.

    AIMS supports clients that conduct studies through CROs and trial sites but need stronger experience in study planning, project management, issue resolution, quality oversight, documentation, and interpretation.

    View more
  • 4/6

    NAMs and MIDD Strategy & Execution Support

    Connect NAMs and MIDD to evidence generation and interpretation strategies for specific development questions.

    AIMS defines the scope of NAMs and MIDD according to pipeline stage and decision purpose, then links nonclinical and clinical evidence quantitatively for dose, population, study design, regulatory explanation, and partner communication.

    View more
  • 5/6

    Global Inbound / Outbound Development Strategy

    Plan data use, clinical/regulatory pathways, and execution sequence for the target country or market.

    AIMS proposes executable development paths for inbound Korea development and outbound global development by reviewing existing data usability, additional evidence needs, target countries, regulatory expectations, cost, and timeline.

    View more
  • 6/6

    Early-stage Development Guide for Advanced Biotherapeutics

    Translate basic research outputs into CMC, nonclinical, and clinical entry plans.

    AIMS reviews manufacturability, quality attributes, analytical methods, nonclinical evaluation feasibility, cost, and timeline to determine development readiness and priority tasks for advanced biotherapeutic candidates.

    View more

Expertise, Network
& Execution

Extensive network with regulators, CROs, hospitals and industry leaders.

End-to-end support from preclinical development to commercialization.

View more
0+ Clients
0+ Successful projects

Insights & Resources

AIMS UPDATE 2026.08 vol.29 AIMS UPDATE 2026.07 vol.28 AIMS UPDATE 2026.06 vol.27
View more

Contact Us

For an ongoing project, please use the personal contact information of the designee.

+82.2.533.8460 contact@aimsbiosci.com